BioCentury | Dec 3, 2020

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen Horowitz, Menlo Ventures, Radical Ventures,...
BioCentury | Dec 2, 2020

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...
BioCentury | Aug 15, 2020

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

While CBMG’s $383 million take private deal was put in motion before U.S. officials further ratcheted up pressure on U.S- listed Chinese companies, the move highlights the trade-offs Chinese companies face in considering where to...
BioCentury | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

Kodiak in $225M royalty deal with Baker Bros. Kodiak Sciences Inc. (NASDAQ:KOD) gained $21.45 (72%) to $51.05 on Monday after selling royalty rights on global net sales of retinal vascular disease drug KSI-301 to Baker...
BioCentury | Nov 14, 2019
Company News

Nov. 13 Company Quick Takes: FDA panel rebuffs Jardiance; plus Nucala, Cellular Biomedicine, BeiGene, Autolus and Noile-Immune

Panel rebuffs Jardiance for Type I diabetes FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 14-2 Wednesday that available data do not support approval of Jardiance empagliflozin from Boehringer Ingelheim GmbH. The panel was asked...
BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR...
BioCentury | Jul 19, 2019
Financial News

Genmab’s plans after $500M NASDAQ debut

European bellwether Genmab plans to use a large chunk of the $505.9 million it raised through its listing on NASDAQ Thursday to fuel clinical development and commercialization of antibody-drug conjugate tisotumab vedotin (HuMax-TF-ADC). Two other...
BioCentury | Jul 2, 2019
Preclinical News

July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

Semma to bring stem cell-derived islet therapies for diabetes to clinic in 2020 Semma Therapeutics Inc. (Cambridge, Mass.) plans to start Phase I testing in early 2020 of its stem cell-derived islets combined with immunosuppression...
BioCentury | May 16, 2019
Company News

May 16 Company Quick Takes: Iconic oncology deals; plus Zymeworks-GSK, Aimmune and more

Iconic in pair of deals to develop lead oncology program Iconic Therapeutics Inc. (South San Francisco, Calif.) granted Exelixis Inc. (NASDAQ:EXEL) an option to license ICON-2 for $7.5 million up front and funding for preclinical...
BioCentury | May 8, 2019
Financial News

May 8 Financial Quick Takes: Trevi IPO, BMS, GeneQuantum

Trevi prices $55M IPO below range Trevi Therapeutics Inc. (NASDAQ:TRVI) shares gained back some ground Wednesday -- adding $0.34 to $8.23 for the day -- after tumbling out of the gate on Tuesday, when it...
Items per page:
1 - 10 of 253